Stryker completes acquisition of MOLLI Surgical
Stryker (NYSE:SYK) has completed the acquisition of MOLLI Surgical Inc., a private company specializing in wire-free soft tissue localization technology for breast conserving surgery. This acquisition strengthens Stryker's commitment to advancing surgical solutions in breast cancer care. The MOLLI 2 localization system offers ease of use and reliability for efficient surgical workflows. Key features include:
- MOLLI Marker: Smallest on the market at 3.2 mm, detectable in dense breasts and through hematoma
- MOLLI 2 tablet: Provides surgeons with real-time feedback including distance, visual, auditory, and 3D directional guidance
This acquisition complements Stryker's existing breast cancer portfolio, which includes SPY fluorescence imaging technology for lymphatic mapping and lighted retractors.
Stryker (NYSE:SYK) ha completato l'acquisizione di MOLLI Surgical Inc., un'azienda privata specializzata nella tecnologia di localizzazione dei tessuti molli senza fili per la chirurgia conservativa del seno. Questa acquisizione rafforza l'impegno di Stryker nel promuovere soluzioni chirurgiche per la cura del cancro al seno. Il sistema di localizzazione MOLLI 2 offre facilità d'uso e affidabilità per flussi di lavoro chirurgici efficienti. Le caratteristiche principali includono:
- Marker MOLLI: il più piccolo sul mercato con un diametro di 3.2 mm, rilevabile in seno denso e attraverso ematomi
- Tablet MOLLI 2: fornisce ai chirurghi feedback in tempo reale, compresi distanza, indicazioni visive, uditive e guida direzionale 3D
Questa acquisizione completa il portafoglio esistente di Stryker per la cura del cancro al seno, che include la tecnologia di imaging a fluorescenza SPY per la mappatura linfatica e i retrattori illuminati.
Stryker (NYSE:SYK) ha completado la adquisición de MOLLI Surgical Inc., una empresa privada especializada en tecnología de localización de tejidos blandos sin cables para la cirugía conservadora del seno. Esta adquisición refuerza el compromiso de Stryker con el avance de soluciones quirúrgicas en el cuidado del cáncer de mama. El sistema de localización MOLLI 2 ofrece facilidad de uso y confiabilidad para flujos de trabajo quirúrgicos eficientes. Las características clave incluyen:
- Marcador MOLLI: el más pequeño del mercado con un diámetro de 3.2 mm, detectable en senos densos y a través de hematomas
- Tableta MOLLI 2: proporciona a los cirujanos retroalimentación en tiempo real que incluye distancia, guía visual, auditiva y direccional en 3D
Esta adquisición complementa la cartera existente de Stryker para el cáncer de mama, que incluye tecnología de imagen fluorescente SPY para mapeo linfático y retractores iluminados.
스트라이커(Stryker, NYSE:SYK)는 MOLLI Surgical Inc.를 인수했습니다. MOLLI Surgical Inc.는 유방 보존 수술을 위한 무선 연조직 위치 확인 기술을 전문으로 하는 사설 회사입니다. 이번 인수는 유방암 치료를 위한 외과 솔루션을 발전시키려는 스트라이커의 의지를 강화합니다. MOLLI 2 위치 확인 시스템은 효율적인 수술 워크플로우를 위한 사용 편의성과 신뢰성을 제공합니다. 주요 특징은 다음과 같습니다:
- MOLLI 마커: 시장에서 가장 작은 크기인 3.2mm로, 밀도가 높은 유방 및 혈종을 통해 감지 가능
- MOLLI 2 태블릿: 외과 의사에게 거리, 시각적, 청각적 및 3D 방향 안내를 포함한 실시간 피드백 제공
이번 인수는 림프 매핑을 위한 SPY 형광 이미징 기술과 조명 리트랙터를 포함한 스트라이커의 기존 유방암 포트폴리오를 보완합니다.
Stryker (NYSE:SYK) a achevé l'acquisition de MOLLI Surgical Inc., une entreprise privée spécialisée dans la technologie de localisation de tissus mous sans fil pour la chirurgie conservatrice du sein. Cette acquisition renforce l'engagement de Stryker à faire progresser les solutions chirurgicales dans le domaine des soins du cancer du sein. Le système de localisation MOLLI 2 offre une facilité d'utilisation et une fiabilité pour des flux de travail chirurgicaux efficaces. Les principales caractéristiques incluent:
- Marqueur MOLLI : le plus petit sur le marché avec 3.2 mm, détectable dans les seins denses et à travers les hématomes
- Tablette MOLLI 2 : fournit aux chirurgiens un retour d'information en temps réel, y compris la distance, des indications visuelles, auditives et directionnelles en 3D
Cette acquisition complète le portefeuille existant de Stryker pour le cancer du sein, qui comprend la technologie d'imagerie par fluorescence SPY pour la cartographie lymphatique et les retracteurs éclairés.
Stryker (NYSE:SYK) hat die Übernahme von MOLLI Surgical Inc. abgeschlossen, einem privaten Unternehmen, das auf kabellose Lokalisierungstechnologie für weiches Gewebe bei brustbewahrenden Operationen spezialisiert ist. Diese Übernahme stärkt Strykers Engagement für die Weiterentwicklung chirurgischer Lösungen in der Brustkrebsversorgung. Das MOLLI 2 Lokalisierungssystem bietet Benutzerfreundlichkeit und Zuverlässigkeit für effiziente chirurgische Arbeitsabläufe. Zu den Hauptmerkmalen gehören:
- MOLLI Marker: Der kleinste auf dem Markt mit 3.2 mm, erkennbar bei dichten Brüsten und durch Hämatome
- MOLLI 2 Tablet: Bietet Chirurgen Echtzeit-Feedback, einschließlich Distanz, visuelle, akustische und 3D-Richtungsanweisungen
Diese Übernahme ergänzt das bestehende Brustkrebsportfolio von Stryker, das die SPY-Fluoreszenzbildgebungstechnologie für die lymphatische Kartierung und beleuchtete Retraktoren umfasst.
- Acquisition strengthens Stryker's position in breast cancer surgical solutions
- MOLLI 2 system offers advanced features for improved surgical efficiency
- Complements existing Stryker portfolio in breast cancer space
- None.
Insights
Stryker's acquisition of MOLLI Surgical marks a strategic move to bolster its position in the breast cancer care market. While the financial terms weren't disclosed, this acquisition could potentially impact Stryker's revenue streams positively in the medium to long term.
The global breast cancer diagnostics market is projected to reach
Investors should note that this acquisition aligns with Stryker's strategy of expanding through targeted acquisitions in high-growth segments. The synergy between MOLLI's technology and Stryker's existing SPY fluorescence imaging technology could potentially lead to improved market penetration and cross-selling opportunities.
However, the immediate financial impact may be given MOLLI's status as a privately held company, likely with modest revenues. The true value of this acquisition lies in its potential to enhance Stryker's long-term growth prospects in the oncology surgery market.
The acquisition of MOLLI Surgical by Stryker represents a significant advancement in breast cancer surgical technology. The MOLLI 2 localization system's wire-free approach addresses a critical challenge in breast-conserving surgeries, potentially improving surgical precision and patient outcomes.
Key technological advantages of the MOLLI system include:
- A 3.2 mm marker, the smallest in the market, enhancing placement accuracy
- Detectability in dense breasts and through hematoma, expanding its applicability
- Four types of real-time feedback, including 3D directional guidance, potentially reducing surgical time and improving accuracy
These features could significantly enhance the standard of care in breast cancer surgeries. The system's design for ease of use and reliability may also lead to faster adoption rates among surgeons.
The integration of MOLLI's technology with Stryker's existing SPY fluorescence imaging for lymphatic mapping creates a comprehensive suite of tools for breast cancer surgeries. This synergy could potentially reduce the need for repeat surgeries and improve overall patient outcomes.
From a research perspective, this acquisition opens up possibilities for further innovations in minimally invasive breast cancer treatments, potentially leading to reduced recovery times and improved quality of life for patients.
The MOLLI 2 localization system is designed for ease of use and reliability to support a more efficient surgical workflow. The MOLLI Marker is the smallest on the market at 3.2 mm and is detectable in dense breasts and through hematoma. The MOLLI 2 tablet provides surgeons with four real-time types of feedback: distance, visual, auditory and 3D directional guidance.
"Stryker is dedicated to helping oncology surgeons advance surgical treatment through continual innovation and strategic partnerships," said Andrés Rosales, vice president and general manager of Stryker's Endoscopy business. "The acquisition of MOLLI Surgical represents a significant step forward in our goal to provide surgeons with the most advanced tools to improve patient care. MOLLI Surgical complements our existing portfolio in the breast cancer space, which includes our SPY fluorescence imaging technology for lymphatic mapping and lighted retractors."
About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.
Media contact
Sherri Oakson
Stryker
Senior Director, Communications, MedSurg and Neurotechnology Group
sherri.oakson@stryker.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/stryker-completes-acquisition-of-molli-surgical-302210345.html
SOURCE Stryker
FAQ
What company did Stryker (SYK) acquire on July 31, 2024?
What are the key features of MOLLI Surgical's technology acquired by Stryker (SYK)?
How does the MOLLI Surgical acquisition complement Stryker's (SYK) existing portfolio?
What is the significance of the MOLLI Surgical acquisition for Stryker (SYK) in the breast cancer care market?
